Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy

SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 13; no. 1; pp. 287 - 294
Main Authors Bala, Vaskor, Rao, Shasha, Li, Peng, Wang, Shudong, Prestidge, Clive A
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 04.01.2016
Subjects
Online AccessGet full text
ISSN1543-8384
1543-8392
DOI10.1021/acs.molpharmaceut.5b00785

Cover

Abstract SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their ability to improve oral absorption and bioavailability of lipid soluble and highly permeable compounds. Thus, this study has focused on improving solubility in lipid excipients, controlling stability, and enhancing transmucosal permeability of SN38 by specific chemical modification. To achieve these aims, a series of lipophilic prodrugs were designed and synthesized by esterification at the C10 and/or C20 positon(s) of SN38 with dietary fatty acids of diverse hydrocarbon chain lengths. The solubility of these novel prodrugs in long-chain triglycerides was increased up to 444-fold, and cytotoxicity was significantly reduced in comparison to SN38. The prodrugs were stable in simulated gastric fluids but exhibited different rates of hydrolysis (t 1/2 < 5 min to t 1/2 > 2 h) in simulated intestinal fluids (in the presence of enzymes) depending on the alkyl chain length and the position modified. A predictable reconversion of prodrugs to SN38 in plasma was also confirmed. On the basis of these studies, SN38-undecanoate (C20) was identified as the optimal prodrug. Finally, in vitro permeability and uptake studies in rat intestinal mucosal membrane using an Ussing chamber showed significant improvement in transepithelial drug transport and cellular uptake. Together, these results indicate that well designed lipophilic prodrugs have potential for the efficacious and safe oral delivery of SN38.
AbstractList SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their ability to improve oral absorption and bioavailability of lipid soluble and highly permeable compounds. Thus, this study has focused on improving solubility in lipid excipients, controlling stability, and enhancing transmucosal permeability of SN38 by specific chemical modification. To achieve these aims, a series of lipophilic prodrugs were designed and synthesized by esterification at the C10 and/or C20 positon(s) of SN38 with dietary fatty acids of diverse hydrocarbon chain lengths. The solubility of these novel prodrugs in long-chain triglycerides was increased up to 444-fold, and cytotoxicity was significantly reduced in comparison to SN38. The prodrugs were stable in simulated gastric fluids but exhibited different rates of hydrolysis (t 1/2 < 5 min to t 1/2 > 2 h) in simulated intestinal fluids (in the presence of enzymes) depending on the alkyl chain length and the position modified. A predictable reconversion of prodrugs to SN38 in plasma was also confirmed. On the basis of these studies, SN38-undecanoate (C20) was identified as the optimal prodrug. Finally, in vitro permeability and uptake studies in rat intestinal mucosal membrane using an Ussing chamber showed significant improvement in transepithelial drug transport and cellular uptake. Together, these results indicate that well designed lipophilic prodrugs have potential for the efficacious and safe oral delivery of SN38.
SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their ability to improve oral absorption and bioavailability of lipid soluble and highly permeable compounds. Thus, this study has focused on improving solubility in lipid excipients, controlling stability, and enhancing transmucosal permeability of SN38 by specific chemical modification. To achieve these aims, a series of lipophilic prodrugs were designed and synthesized by esterification at the C10 and/or C20 positon(s) of SN38 with dietary fatty acids of diverse hydrocarbon chain lengths. The solubility of these novel prodrugs in long-chain triglycerides was increased up to 444-fold, and cytotoxicity was significantly reduced in comparison to SN38. The prodrugs were stable in simulated gastric fluids but exhibited different rates of hydrolysis (t1/2 < 5 min to t1/2 > 2 h) in simulated intestinal fluids (in the presence of enzymes) depending on the alkyl chain length and the position modified. A predictable reconversion of prodrugs to SN38 in plasma was also confirmed. On the basis of these studies, SN38-undecanoate (C20) was identified as the optimal prodrug. Finally, in vitro permeability and uptake studies in rat intestinal mucosal membrane using an Ussing chamber showed significant improvement in transepithelial drug transport and cellular uptake. Together, these results indicate that well designed lipophilic prodrugs have potential for the efficacious and safe oral delivery of SN38.
Author Wang, Shudong
Bala, Vaskor
Rao, Shasha
Li, Peng
Prestidge, Clive A
AuthorAffiliation School of Pharmacy and Medical Sciences
University of South Australia
AuthorAffiliation_xml – name: School of Pharmacy and Medical Sciences
– name: University of South Australia
Author_xml – sequence: 1
  givenname: Vaskor
  surname: Bala
  fullname: Bala, Vaskor
– sequence: 2
  givenname: Shasha
  surname: Rao
  fullname: Rao, Shasha
– sequence: 3
  givenname: Peng
  surname: Li
  fullname: Li, Peng
– sequence: 4
  givenname: Shudong
  surname: Wang
  fullname: Wang, Shudong
– sequence: 5
  givenname: Clive A
  surname: Prestidge
  fullname: Prestidge, Clive A
  email: Clive.Prestidge@unisa.edu.au
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26623947$$D View this record in MEDLINE/PubMed
BookMark eNqNkF1LwzAUhoNM3If-BYk_YDNJkzb1RmT4BcMJU--kpEnqMtqmJCkyf72d2wS92tU5cN73Pec8Q9Crba0BuMBoghHBl0L6SWXLZilcJaRuw4TlCCWcHYEBZjQa8yglvd-e0z4Yer9CiFBGohPQJ3FMopQmA_A-M41tlqY0Ej47q1z74aEt4OIp4ldwsa7DUnvjoagVNDV8M8FZOO0WCxm0M18iGFvDYD-FU3DuRNkNdWU7lxPN-hQcF6L0-mxXR-D17vZl-jCeze8fpzezsaAkDWPOEEcJponWRElEUsUojgslCh1zSQqkFOMc5ThWOMk3t0spE0G4jBIa5SIagfNtbtPmlVZZ40wl3Drb_9kJrrcC6az3TheZNOHn9uCEKTOMsg3ZrCOb_SGb7ch2Cem_hP2SQ7xs691IVrZ1dQfjAN83rj2Zeg
CitedBy_id crossref_primary_10_1016_j_ejps_2020_105340
crossref_primary_10_1039_C8BM00947C
crossref_primary_10_1080_10601325_2023_2242409
crossref_primary_10_1016_j_jconrel_2018_07_022
crossref_primary_10_1021_acsbiomaterials_7b00023
crossref_primary_10_1016_j_phrs_2019_104398
crossref_primary_10_1016_j_colsurfb_2019_06_020
crossref_primary_10_1016_j_ijpharm_2023_122886
crossref_primary_10_1016_j_ajps_2024_100908
crossref_primary_10_1186_s12951_022_01257_4
crossref_primary_10_3390_molecules28134931
crossref_primary_10_36290_csf_2020_027
crossref_primary_10_1016_j_bmc_2017_04_025
crossref_primary_10_1007_s11095_021_03093_x
crossref_primary_10_1021_acs_molpharmaceut_6b01027
crossref_primary_10_1007_s13346_021_00903_y
crossref_primary_10_1038_s44222_023_00082_0
crossref_primary_10_1016_j_ejphar_2020_172937
crossref_primary_10_1111_jphp_12984
crossref_primary_10_1039_C8TB02319K
crossref_primary_10_1016_j_ijpharm_2018_08_010
crossref_primary_10_1208_s12249_018_1272_0
crossref_primary_10_1016_j_ejmech_2019_06_009
crossref_primary_10_1016_j_jconrel_2020_10_036
crossref_primary_10_1016_j_colsurfb_2023_113736
crossref_primary_10_1021_acsbiomaterials_9b00689
crossref_primary_10_1021_acs_molpharmaceut_1c00761
crossref_primary_10_1007_s13346_018_0543_3
crossref_primary_10_1007_s13404_024_00346_6
crossref_primary_10_3389_fphar_2022_879660
crossref_primary_10_1007_s00894_023_05455_1
crossref_primary_10_1016_j_ejpb_2018_10_018
crossref_primary_10_1080_15421406_2020_1743447
crossref_primary_10_1002_med_21533
crossref_primary_10_1016_j_addr_2016_04_007
crossref_primary_10_1016_j_jconrel_2021_12_003
crossref_primary_10_3390_nu12041173
crossref_primary_10_4155_fmc_2019_0155
crossref_primary_10_1016_j_msec_2020_111332
crossref_primary_10_3390_pharmaceutics16121613
crossref_primary_10_1016_j_addr_2020_10_002
crossref_primary_10_1016_j_ijpharm_2021_120399
crossref_primary_10_1039_D4FO00906A
crossref_primary_10_1021_acs_molpharmaceut_6b00591
crossref_primary_10_1016_j_ejmech_2019_04_074
crossref_primary_10_3390_molecules28093936
crossref_primary_10_3390_pharmaceutics11110569
crossref_primary_10_1007_s00280_018_3720_7
crossref_primary_10_1016_j_ijpharm_2019_118499
crossref_primary_10_1016_j_procbio_2020_09_010
crossref_primary_10_1039_C9TB01270B
crossref_primary_10_1021_acs_bioconjchem_7b00774
crossref_primary_10_1080_21691401_2021_1907393
crossref_primary_10_1002_slct_201903035
Cites_doi 10.1016/j.jconrel.2012.12.019
10.1016/j.jconrel.2013.07.022
10.1021/jm401644v
10.1146/annurev.bi.54.070185.003313
10.1016/j.ejpb.2014.12.014
10.1023/A:1018890106045
10.1016/j.jconrel.2013.12.031
10.3109/00498254.2011.646339
10.1002/9783527633166.ch4
10.1016/j.ecoenv.2010.03.006
10.1038/nrc1977
10.1021/jo000221n
10.1007/978-1-4614-0323-4_9
10.1016/j.jconrel.2014.12.030
10.1152/ajpgi.90649.2008
10.1021/cr0780210
10.1158/1078-0432.CCR-1585-3
10.1023/A:1012148300807
10.1111/j.1749-6632.2000.tb07031.x
10.1124/jpet.103.052522
10.1016/S0090-9556(24)15060-X
10.1158/1535-7163.TARG-09-C218
10.1038/nrd2197
10.1021/cr900097c
10.1016/j.jconrel.2010.11.022
10.1111/j.1749-6632.2000.tb07040.x
10.1038/sj.bjc.6600591
10.1016/j.addr.2011.05.019
10.1002/pbc.25105
10.1021/bc100094z
10.1038/84635
10.2174/1389200033489253
10.1016/j.addr.2007.10.014
10.1016/j.ejps.2012.10.007
10.1016/j.ejpb.2011.01.021
10.1021/bc700333s
10.1021/jm9607562
10.1200/JCO.2008.20.6300
10.1200/JCO.2000.18.3.659
10.1097/CAD.0b013e32835c3543
10.1002/anie.197805221
10.1021/jm0309957
10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V
10.1038/35077241
10.1088/0957-4484/24/24/245101
ContentType Journal Article
Copyright Copyright © 2015 American Chemical Society
Copyright_xml – notice: Copyright © 2015 American Chemical Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1021/acs.molpharmaceut.5b00785
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1543-8392
EndPage 294
ExternalDocumentID 26623947
10_1021_acs_molpharmaceut_5b00785
b46531779
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
123
53G
55A
7~N
AABXI
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
H~9
IH9
JG
JG~
P2P
RNS
ROL
UI2
VF5
VG9
W1F
X
---
-~X
4.4
5VS
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ADHLV
AHGAQ
BAANH
CITATION
CUPRZ
GGK
CGR
CUY
CVF
ECM
EIF
NPM
ID FETCH-LOGICAL-a429t-850807147ee2dc029d5416fdafe68c2f0dd5880b16d17b6623ccc7a28c3743ba3
IEDL.DBID ACS
ISSN 1543-8384
IngestDate Thu Jan 02 22:24:03 EST 2025
Thu Apr 24 22:59:20 EDT 2025
Wed Oct 01 06:02:37 EDT 2025
Thu Aug 27 13:42:32 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords drug delivery
simulated gastric/intestinal conditions
lipophilic prodrug
cytotoxicity
SN38 (7-ethyl-10-hydorxy camptothecin)
permeability
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a429t-850807147ee2dc029d5416fdafe68c2f0dd5880b16d17b6623ccc7a28c3743ba3
PMID 26623947
PageCount 8
ParticipantIDs pubmed_primary_26623947
crossref_citationtrail_10_1021_acs_molpharmaceut_5b00785
crossref_primary_10_1021_acs_molpharmaceut_5b00785
acs_journals_10_1021_acs_molpharmaceut_5b00785
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-01-04
PublicationDateYYYYMMDD 2016-01-04
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-04
  day: 04
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2016
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref45/cit45
ref27/cit27
ref16/cit16
ref23/cit23
ref31/cit31
ref2/cit2
ref34/cit34
Moridani M. Y. (ref20/cit20) 2010
ref37/cit37
Sparreboom A. (ref10/cit10) 1998; 4
ref17/cit17
ref35/cit35
ref19/cit19
ref21/cit21
ref42/cit42
ref46/cit46
ref49/cit49
Marchand C. (ref3/cit3) 2012
ref13/cit13
ref24/cit24
ref38/cit38
Lundberg B. (ref48/cit48) 1998; 13
ref50/cit50
ref6/cit6
ref36/cit36
Mathijssen R. H. J. (ref8/cit8) 2001; 7
ref18/cit18
ref11/cit11
ref25/cit25
ref29/cit29
Slatter J. G. (ref9/cit9) 2000; 28
ref32/cit32
ref39/cit39
ref14/cit14
ref5/cit5
ref51/cit51
ref43/cit43
ref28/cit28
ref40/cit40
ref26/cit26
ref12/cit12
ref15/cit15
Takimoto C. H. (ref44/cit44) 2000; 18
ref41/cit41
ref22/cit22
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref7/cit7
References_xml – ident: ref42/cit42
  doi: 10.1016/j.jconrel.2012.12.019
– ident: ref12/cit12
  doi: 10.1016/j.jconrel.2013.07.022
– ident: ref43/cit43
  doi: 10.1021/jm401644v
– ident: ref1/cit1
  doi: 10.1146/annurev.bi.54.070185.003313
– ident: ref35/cit35
  doi: 10.1016/j.ejpb.2014.12.014
– ident: ref33/cit33
  doi: 10.1023/A:1018890106045
– ident: ref27/cit27
  doi: 10.1016/j.jconrel.2013.12.031
– ident: ref49/cit49
  doi: 10.3109/00498254.2011.646339
– volume: 7
  start-page: 2182
  issue: 8
  year: 2001
  ident: ref8/cit8
  publication-title: Clin. Cancer Res.
– start-page: 79
  volume-title: Prodrugs and Targeted Delivery
  year: 2010
  ident: ref20/cit20
  doi: 10.1002/9783527633166.ch4
– ident: ref30/cit30
  doi: 10.1016/j.ecoenv.2010.03.006
– ident: ref2/cit2
  doi: 10.1038/nrc1977
– ident: ref39/cit39
  doi: 10.1021/jo000221n
– start-page: 175
  volume-title: DNA Topoisomerases and Cancer
  year: 2012
  ident: ref3/cit3
  doi: 10.1007/978-1-4614-0323-4_9
– ident: ref23/cit23
  doi: 10.1016/j.jconrel.2014.12.030
– ident: ref32/cit32
  doi: 10.1152/ajpgi.90649.2008
– volume: 13
  start-page: 453
  issue: 5
  year: 1998
  ident: ref48/cit48
  publication-title: Anticancer Drug Des.
– ident: ref5/cit5
  doi: 10.1021/cr0780210
– ident: ref45/cit45
  doi: 10.1158/1078-0432.CCR-1585-3
– ident: ref47/cit47
  doi: 10.1023/A:1012148300807
– ident: ref37/cit37
  doi: 10.1111/j.1749-6632.2000.tb07031.x
– ident: ref21/cit21
  doi: 10.1124/jpet.103.052522
– volume: 28
  start-page: 423
  issue: 4
  year: 2000
  ident: ref9/cit9
  publication-title: Drug Metab. Dispos.
  doi: 10.1016/S0090-9556(24)15060-X
– ident: ref17/cit17
  doi: 10.1158/1535-7163.TARG-09-C218
– ident: ref22/cit22
  doi: 10.1038/nrd2197
– volume: 4
  start-page: 2747
  issue: 11
  year: 1998
  ident: ref10/cit10
  publication-title: Clin. Cancer Res.
– ident: ref4/cit4
  doi: 10.1021/cr900097c
– ident: ref15/cit15
  doi: 10.1016/j.jconrel.2010.11.022
– ident: ref36/cit36
  doi: 10.1111/j.1749-6632.2000.tb07040.x
– ident: ref13/cit13
  doi: 10.1038/sj.bjc.6600591
– ident: ref25/cit25
  doi: 10.1016/j.addr.2011.05.019
– ident: ref41/cit41
  doi: 10.1002/pbc.25105
– ident: ref14/cit14
  doi: 10.1021/bc100094z
– ident: ref18/cit18
– ident: ref50/cit50
  doi: 10.1038/84635
– ident: ref34/cit34
– ident: ref19/cit19
  doi: 10.2174/1389200033489253
– ident: ref24/cit24
  doi: 10.1016/j.addr.2007.10.014
– ident: ref46/cit46
  doi: 10.1016/j.ejps.2012.10.007
– ident: ref16/cit16
  doi: 10.1016/j.ejpb.2011.01.021
– ident: ref29/cit29
  doi: 10.1021/bc700333s
– ident: ref38/cit38
  doi: 10.1021/jm9607562
– ident: ref11/cit11
  doi: 10.1200/JCO.2008.20.6300
– volume: 18
  start-page: 659
  issue: 3
  year: 2000
  ident: ref44/cit44
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2000.18.3.659
– ident: ref40/cit40
  doi: 10.1097/CAD.0b013e32835c3543
– ident: ref28/cit28
  doi: 10.1002/anie.197805221
– ident: ref31/cit31
  doi: 10.1021/jm0309957
– ident: ref7/cit7
– ident: ref26/cit26
  doi: 10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V
– ident: ref51/cit51
  doi: 10.1038/35077241
– ident: ref6/cit6
  doi: 10.1088/0957-4484/24/24/245101
SSID ssj0024523
Score 2.3852782
Snippet SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted...
SourceID pubmed
crossref
acs
SourceType Index Database
Enrichment Source
Publisher
StartPage 287
SubjectTerms Camptothecin - analogs & derivatives
Camptothecin - chemistry
Cell Survival - drug effects
Drug Delivery Systems - methods
HCT116 Cells
Humans
Prodrugs - adverse effects
Prodrugs - chemical synthesis
Prodrugs - chemistry
Tandem Mass Spectrometry
Title Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy
URI http://dx.doi.org/10.1021/acs.molpharmaceut.5b00785
https://www.ncbi.nlm.nih.gov/pubmed/26623947
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVABC
  databaseName: American Chemical Society Journals
  customDbUrl:
  eissn: 1543-8392
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024523
  issn: 1543-8384
  databaseCode: ACS
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: https://pubs.acs.org/action/showPublications?display=journals
  providerName: American Chemical Society
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS8MwFA5eQHzxfpk3Isie1tmmSZv6JsMh4mWwTfYiJbfKUNuxdg_z15u03cb0we219JQkPT3n60m-7wBwFXBEuIOZhR2kLBw42OK2p6xICtfnkWnFbfjOT8_efRc_9EhvxuP-vYOPnGsm0vpXYoinZYm3TrhJbGQVrCOPOuaP67bRngnskbynm4YGrkVdijfA5b-PMqlJpHOpaQ5k5smmuQ06E8pOccbkoz7KeF18_1VwXGYeO2CrBJ_wtvCWXbCi4j1QbRX3jmuwMyNjpTVYha2ZrvV4H7w99gfJwBRgBGzpuDscvacwiWD72aU3sD2ONZZM-ylksYT9GL72s2ECG1NB6ILvCbP8nC58GeqBGLWCkgE2PgDd5l2ncW-V3RkspnNYZlEN7Qz7yVcKSWGjQBIN7iLJIuVRgSJbSqKDA3c86fjc0zBLCOEzRLUTYJcz9xCsxUmsjgGUigbUo7bUwQBLghhzkR95hNnMqNWICtDOlYbl15WG-cY5ckJzcW5Jw3JJK4BO3mQoSq1z03LjcxFTNDUdFIIfixgdFe4yNUFmwgH2T5Yd-inY1JisqPLgM7CWDUfqXOOejF_kfv4Dg94DXw
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dT9swFL0aIAEv43NbxwZGQjyRkjh24uxtqoYKlFKpBSEhFPkrqIIlVZM-dL9-dpK1Ki8DXq1c69q-8T2yfc4FOIoEpsIj3CEe1g6JPOIIN9BOoqQfisSW4rZ856tu0L4hF3f0rn5Vabkwxonc9JSXl_hzdQHv1Lb9ziz_tD7pbVJh8xtdgpVSEcXColZ_rrNHy9JuBiH4DvMZWYXD_3ZlM5TMFzLUAtYsc87ZBtzPvC2fmjw1J4Voyj8vhBzfN5xN-FhDUfSzip0t-KDTbTjuVd9OT9BgTs3KT9Ax6s1Vrqc78NAZjrKRPY6RqGd24fHkMUdZgvpdn_1A_WlqkGU-zBFPFRqm6HZYjDPUmslDV-xPVJSvdtH12DhitQtqPth0F27Ofg1abaeu1eBwk9EKhxmgZ7lQodZYSRdHihqolyie6IBJnLhKUbNVCC9QXigCA7qklCHHzIQE8QX3P8FymqX6CyClWcQC5iqzNRBFMec-DpOAcpdb7RrZADujcf2v5XF5jY692DYuTGlcT2kD2L8FjWWtfG4LcDy_xhTPTEeV_MdrjD5XUTMzwXbAEQm_vtX1A1hrD646cee8e7kH6watVec_5BssF-OJ_m4QUSH2y9D_C6MjC8o
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NTZp4YYyPMTaGkdCeli5x7MTZGypUA0ap1A3tBUX-ylQBSdWkD-Wvx5eYVuVlY69Wzjo757ufzr7fAbzNFOUqYjJgEbUByyIWqDCxQWF0nKoCW3FjvfOXYXJ-xT5d82ufcMNaGKdE7Waq20t8PNVTU3iGgegUx39VWIPqs709rjDG8QewxZEKDqFRf7zi2uNtezeHEuJAxIJtw5tbp8Iopeu1KLWGN9u4M9iBfKlx-9zkR2_eqJ7-_Q-Z4_2X9BgeeUhK3nU2tAsbtnwCx6Pu28UJuVyVaNUn5JiMVmzXi6fw_WIyraaYltFk5LzxbH5Tk6og42Eszsh4UTqEWU9qIktDJiX5NmlmFekvaaK7KlDStK93ydeZUwQ5DHxd2OIZXA0-XPbPA9-zIZAusjWBcIAPa6JSa6nRIc0Md5CvMLKwidC0CI3hzmWoKDFRqhIHvrTWqaTCmQaLlYyfw2ZZlfYFEGNFJhIRGucimOFUypimRcJlKJHDRu8D7mruz1ydt9fpNMpxcG1Lc7-l-yD-_tRcewZ0bMTx8y6idCk67WhA7iK011nOUoTigjOWvvxf1V_D9uj9IL_4OPx8AA8daOvSQOwQNpvZ3L5ywKhRR631_wEBJw5E
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lipophilic+Prodrugs+of+SN38%3A+Synthesis+and+in+Vitro+Characterization+toward+Oral+Chemotherapy&rft.jtitle=Molecular+pharmaceutics&rft.au=Bala%2C+Vaskor&rft.au=Rao%2C+Shasha&rft.au=Li%2C+Peng&rft.au=Wang%2C+Shudong&rft.date=2016-01-04&rft.pub=American+Chemical+Society&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=13&rft.issue=1&rft.spage=287&rft.epage=294&rft_id=info:doi/10.1021%2Facs.molpharmaceut.5b00785&rft.externalDocID=b46531779
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon